biotech · Relapsed/Refractory Multiple Myeloma · Respiratory Distress Syndrome, Adult · INKT
MiNK Therapeutics
XNK Therapeutics is a biotech organization headquartered in NEW YORK, NY, SE. It trades on NYSE under ticker INKT. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Respiratory Distress Syndro
NEW YORK, NY, SE HQ
2012 Founded
9 Employees
Public company Type
INKT · NYSE Ticker
Company details
- Status
- Public
- HQ
- NEW YORK, NY, SE
- Founded
- 2012
- Employees
- 9
- Programs
- 3
- Drugs
- 1
- Patents
- 6
agenT-797
Phase 1 · small molecule · Relapsed/Refractory Multiple Myeloma
agenT-797 for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at MiNK Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 2019-1305
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MiNK Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Relapsed/Refractory Multiple Myeloma
- Status
- completed
- Trials
- 1